Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Serum levels of TGFβ, IL-10, IL-17, and IL-23 cytokines in β-thalassemia major patients: the impact of silymarin therapy.

Balouchi S, Gharagozloo M, Esmaeil N, Mirmoghtadaei M, Moayedi B.

Immunopharmacol Immunotoxicol. 2014 Aug;36(4):271-4. doi: 10.3109/08923973.2014.926916.

PMID:
24945737
2.

Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial.

Rendina M, D'Amato M, Castellaneta A, Castellaneta NM, Brambilla N, Giacovelli G, Rovati L, Rizzi SF, Zappimbulso M, Bringiotti RS, Di Leo A.

Transpl Int. 2014 Jul;27(7):696-704. doi: 10.1111/tri.12324.

3.

Use of selenium-silymarin mix reduces lower urinary tract symptoms and prostate specific antigen in men.

Vostalova J, Vidlar A, Ulrichova J, Vrbkova J, Simanek V, Student V.

Phytomedicine. 2013 Dec 15;21(1):75-81. doi: 10.1016/j.phymed.2013.07.018.

PMID:
24012146
4.

Impact of oral silymarin on virus- and non-virus-specific T-cell responses in chronic hepatitis C infection.

Adeyemo O, Doi H, Rajender Reddy K, Kaplan DE.

J Viral Hepat. 2013 Jul;20(7):453-62. doi: 10.1111/jvh.12050.

5.

Immunomodulatory effects of silymarin in patients with β-thalassemia major.

Gharagozloo M, Karimi M, Amirghofran Z.

Int Immunopharmacol. 2013 Jun;16(2):243-7. doi: 10.1016/j.intimp.2013.04.016.

PMID:
23624215
6.

A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.

Moayedi B, Gharagozloo M, Esmaeil N, Maracy MR, Hoorfar H, Jalaeikar M.

Eur J Haematol. 2013 Mar;90(3):202-9. doi: 10.1111/ejh.12061.

PMID:
23278124
7.

Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period.

Mariño Z, Crespo G, D'Amato M, Brambilla N, Giacovelli G, Rovati L, Costa J, Navasa M, Forns X.

J Hepatol. 2013 Mar;58(3):415-20. doi: 10.1016/j.jhep.2012.09.034.

PMID:
23063567
8.

The treatment of melasma by silymarin cream.

Altaei T.

BMC Dermatol. 2012 Oct 2;12:18. doi: 10.1186/1471-5945-12-18.

9.

Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.

Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, Doo E, Meyers CM, Reddy KR; Silymarin in NASH and C Hepatitis (SyNCH) Study Group..

JAMA. 2012 Jul 18;308(3):274-82. doi: 10.1001/jama.2012.8265.

10.

Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.

Fallahzadeh MK, Dormanesh B, Sagheb MM, Roozbeh J, Vessal G, Pakfetrat M, Daneshbod Y, Kamali-Sarvestani E, Lankarani KB.

Am J Kidney Dis. 2012 Dec;60(6):896-903. doi: 10.1053/j.ajkd.2012.06.005.

PMID:
22770926
11.

A randomized, double blinded, placebo-controlled clinical trial of silymarin in ulcerative colitis.

Rastegarpanah M, Malekzadeh R, Vahedi H, Mohammadi M, Elahi E, Chaharmahali M, Safarnavadeh T, Abdollahi M.

Chin J Integr Med. 2015 Dec;21(12):902-6. doi: 10.1007/s11655-012-1026-x.

PMID:
22528757
12.
13.

Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial.

Loguercio C, Andreone P, Brisc C, Brisc MC, Bugianesi E, Chiaramonte M, Cursaro C, Danila M, de Sio I, Floreani A, Freni MA, Grieco A, Groppo M, Lazzari R, Lobello S, Lorefice E, Margotti M, Miele L, Milani S, Okolicsanyi L, Palasciano G, Portincasa P, Saltarelli P, Smedile A, Somalvico F, Spadaro A, Sporea I, Sorrentino P, Vecchione R, Tuccillo C, Del Vecchio Blanco C, Federico A.

Free Radic Biol Med. 2012 May 1;52(9):1658-65. doi: 10.1016/j.freeradbiomed.2012.02.008.

PMID:
22343419
14.

Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C.

Reddy KR, Belle SH, Fried MW, Afdhal N, Navarro VJ, Hawke RL, Wahed AS, Doo E, Meyers CM; SyNCH Study Group..

Clin Trials. 2012 Feb;9(1):102-12. doi: 10.1177/1740774511427064.

15.

Effect of silymarin in the treatment of allergic rhinitis.

Bakhshaee M, Jabbari F, Hoseini S, Farid R, Sadeghian MH, Rajati M, Mohamadpoor AH, Movahhed R, Zamani MA.

Otolaryngol Head Neck Surg. 2011 Dec;145(6):904-9. doi: 10.1177/0194599811423504.

PMID:
21952357
16.

Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.

Schrieber SJ, Hawke RL, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ, Meyers CM, Doo E, Fried MW.

Drug Metab Dispos. 2011 Dec;39(12):2182-90. doi: 10.1124/dmd.111.040212.

17.

Comparative effects of silymarin and vitamin E supplementation on oxidative stress markers, and hemoglobin levels among patients on hemodialysis.

Roozbeh J, Shahriyari B, Akmali M, Vessal G, Pakfetrat M, Raees Jalali GA, Afshariani R, Hasheminasab M, Ghahramani N.

Ren Fail. 2011;33(2):118-23. doi: 10.3109/0886022X.2010.541579.

18.

The safety and efficacy of a silymarin and selenium combination in men after radical prostatectomy - a six month placebo-controlled double-blind clinical trial.

Vidlar A, Vostalova J, Ulrichova J, Student V, Krajicek M, Vrbkova J, Simanek V.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Sep;154(3):239-44.

19.

Evaluation of effect of silymarin on granulosa cell apoptosis and follicular development in patients undergoing in vitro fertilization.

Moosavifar N, Mohammadpour AH, Jallali M, Karimiz G, Saberi H.

East Mediterr Health J. 2010 Jun;16(6):642-5. Erratum in: East Mediterr Health J. 2010 Aug;16(8):892.

PMID:
20799592
20.

The iron-chelating potential of silybin in patients with hereditary haemochromatosis.

Hutchinson C, Bomford A, Geissler CA.

Eur J Clin Nutr. 2010 Oct;64(10):1239-41. doi: 10.1038/ejcn.2010.136.

Items per page

Supplemental Content

Loading ...
Support Center